MA40224B1 - Anticorps se liant aux protofibrilles ass améliorés - Google Patents
Anticorps se liant aux protofibrilles ass améliorésInfo
- Publication number
- MA40224B1 MA40224B1 MA40224A MA40224A MA40224B1 MA 40224 B1 MA40224 B1 MA 40224B1 MA 40224 A MA40224 A MA 40224A MA 40224 A MA40224 A MA 40224A MA 40224 B1 MA40224 B1 MA 40224B1
- Authority
- MA
- Morocco
- Prior art keywords
- protofibrils
- ass
- enhanced
- antibodies binding
- antibodies
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 abstract 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 abstract 1
- 230000002776 aggregation Effects 0.000 abstract 1
- 238000004220 aggregation Methods 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 230000006303 immediate early viral mRNA transcription Effects 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
- C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
Abstract
La présente invention concerne le peptide bêta amyloïde (aß) et, plus spécifiquement, des anticorps se liant à des protofibrilles aß et leur utilisation à des fins thérapeutiques et/ou pour le traitement prophylactique de la maladie d'alzheimer et d'autres troubles associés à l'agrégation des protéines aß. En outre, l'invention peut se rapporter au diagnostic de telles maladies, ainsi qu'au suivi de la progression de la maladie grâce à l'utilisation des anticorps de l'invention. En outre, l'invention peut se rapporter à un usage vétérinaire des anticorps de l'invention.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462022952P | 2014-07-10 | 2014-07-10 | |
PCT/EP2015/065633 WO2016005466A2 (fr) | 2014-07-10 | 2015-07-08 | Anticorps se liant aux protofibrilles ass améliorés |
Publications (2)
Publication Number | Publication Date |
---|---|
MA40224A MA40224A (fr) | 2017-05-17 |
MA40224B1 true MA40224B1 (fr) | 2021-05-31 |
Family
ID=53673920
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA40224A MA40224B1 (fr) | 2014-07-10 | 2015-07-08 | Anticorps se liant aux protofibrilles ass améliorés |
MA053887A MA53887A (fr) | 2014-07-10 | 2015-07-08 | Anticorps à liaison protofibrille a-bêta améliorée |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA053887A MA53887A (fr) | 2014-07-10 | 2015-07-08 | Anticorps à liaison protofibrille a-bêta améliorée |
Country Status (33)
Country | Link |
---|---|
US (1) | US9573994B2 (fr) |
EP (2) | EP3865510A3 (fr) |
JP (1) | JP6628786B2 (fr) |
KR (2) | KR20230129449A (fr) |
CN (2) | CN106661103B (fr) |
AR (1) | AR101130A1 (fr) |
AU (1) | AU2015286707B2 (fr) |
CA (1) | CA2951990C (fr) |
CL (1) | CL2017000053A1 (fr) |
CO (1) | CO2017000346A2 (fr) |
CY (1) | CY1124563T1 (fr) |
DK (1) | DK3166970T3 (fr) |
ES (1) | ES2865112T3 (fr) |
HR (1) | HRP20210680T1 (fr) |
HU (1) | HUE053809T2 (fr) |
IL (2) | IL282823B2 (fr) |
JO (1) | JO3537B1 (fr) |
LT (1) | LT3166970T (fr) |
MA (2) | MA40224B1 (fr) |
MX (1) | MX2017000378A (fr) |
MY (1) | MY184890A (fr) |
PE (1) | PE20170768A1 (fr) |
PH (1) | PH12017500032A1 (fr) |
PL (1) | PL3166970T3 (fr) |
PT (1) | PT3166970T (fr) |
RS (1) | RS61717B1 (fr) |
RU (1) | RU2700104C2 (fr) |
SG (1) | SG11201610734RA (fr) |
SI (1) | SI3166970T1 (fr) |
TW (1) | TWI678376B (fr) |
UA (1) | UA121550C2 (fr) |
WO (1) | WO2016005466A2 (fr) |
ZA (1) | ZA201706272B (fr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018522891A (ja) * | 2015-07-21 | 2018-08-16 | バイオアークティック アーベー | 凝集ペプチドを標的とする外傷性脳損傷の治療方法 |
BR112019000098A2 (pt) * | 2016-07-14 | 2019-04-09 | Bioarctic Ab | proteína de fornecimento ao cérebro, método de tratamento e/ou profilaxia de distúrbios cerebrais em mamíferos que possuem ou encontram-se em risco de desenvolver o mencionado distúrbio e método de diagnóstico e/ou detecção de distúrbios cerebrais em mamíferos suspeitos de possuir ou que se encontram em risco de desenvolver o mencionado distúrbio |
US20200299411A9 (en) * | 2016-10-27 | 2020-09-24 | Eisai R&D Management Co., Ltd. | Composition and method for treating alzheimer's disease |
CN111836644B (zh) * | 2018-03-08 | 2024-07-23 | 凡恩世制药(北京)有限公司 | 抗密蛋白18.2抗体及其用途 |
EP3826674A2 (fr) | 2018-07-24 | 2021-06-02 | Eisai R&D Management Co., Ltd. | Méthodes de traitement et de prévention de la maladie d'alzheimer |
BR112023001061A2 (pt) | 2020-07-23 | 2023-04-04 | Othair Prothena Ltd | Anticorpos antiabeta |
TW202300517A (zh) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗類澱粉β抗體及其用途 |
WO2022251048A1 (fr) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anticorps anti-amyloïde bêta et leurs utilisations |
AU2022307687A1 (en) | 2021-07-09 | 2024-01-04 | Eisai R&D Management Co., Ltd. | Biomarkers for alzheimer's disease treatment |
MX2024002567A (es) | 2021-08-30 | 2024-03-20 | Eisai R&D Man Co Ltd | Formulaciones subcutaneas de anticuerpo anti protofibrillas de beta-amiloide (abeta) y metodos de uso de las mismas. |
IL314581A (en) | 2022-02-02 | 2024-09-01 | Eisai R&D Man Co Ltd | Treatment methods using P-TAU181 LEVEL |
CN114578066B (zh) * | 2022-05-07 | 2022-08-19 | 北京第一生物化学药业有限公司 | 检测β-淀粉样蛋白的产品和方法 |
US12084492B2 (en) | 2023-01-20 | 2024-09-10 | Mabwell Therapeutics, Inc. | Anti-amyloid beta protofibril/oligomer antibodies and uses thereof |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5231000A (en) | 1987-10-08 | 1993-07-27 | The Mclean Hospital | Antibodies to A4 amyloid peptide |
WO1991016819A1 (fr) | 1990-04-27 | 1991-11-14 | Molecular Rx., Inc. | Procede et composition servant a traiter des etats pathologiques du systeme nerveux central associes a la proteine beta amyloide anormale |
US5753624A (en) | 1990-04-27 | 1998-05-19 | Milkhaus Laboratory, Inc. | Materials and methods for treatment of plaquing disease |
US6174916B1 (en) | 1990-04-27 | 2001-01-16 | Milkhaus Laboratory, Ltd. | Methods for treating herpes virus infections |
US5604102A (en) | 1992-04-15 | 1997-02-18 | Athena Neurosciences, Inc. | Methods of screening for β-amyloid peptide production inhibitors |
CA2174429C (fr) | 1993-10-27 | 2011-08-30 | Lisa C. Mcconlogue | Animaux transgeniques hebergeant un gene allele app presentant une mutation suedoise |
WO1995031996A1 (fr) | 1994-05-25 | 1995-11-30 | Milkhaus Lab | Compositions et procedes de traitement de maladies a formation de plaque |
US6114133A (en) | 1994-11-14 | 2000-09-05 | Elan Pharmaceuticals, Inc. | Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41) |
US7427392B1 (en) | 1994-11-14 | 2008-09-23 | Elan Pharmaceuticals, Inc. | Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau |
US5786180A (en) | 1995-02-14 | 1998-07-28 | Bayer Corporation | Monoclonal antibody 369.2B specific for β A4 peptide |
US5854215A (en) | 1995-03-14 | 1998-12-29 | Praecis Pharmaceuticals Incorporated | Modulators of β-amyloid peptide aggregation |
US5854204A (en) | 1995-03-14 | 1998-12-29 | Praecis Pharmaceuticals, Inc. | Aβ peptides that modulate β-amyloid aggregation |
US6303567B1 (en) | 1995-03-14 | 2001-10-16 | Praecis Pharmaceuticals, Inc . | Modulators of β-amyloid peptide aggregation comprising D-amino acids |
US5817626A (en) | 1995-03-14 | 1998-10-06 | Praecis Pharmaceuticals Incorporated | Modulators of beta-amyloid peptide aggregation |
US5985242A (en) | 1995-10-27 | 1999-11-16 | Praecis Pharmaceuticals, Inc. | Modulators of β-amyloid peptide aggregation comprising D-amino acids |
JPH09178743A (ja) | 1995-12-27 | 1997-07-11 | Oriental Yeast Co Ltd | 可溶性appの定量法 |
WO1997041856A1 (fr) | 1996-05-08 | 1997-11-13 | Massachusetts Institute Of Technology | LIGANDS ORGANOMETALLIQUES POUR LA LOCALISATION ET LA QUANTIFICATION D'AMYLOIDE IN VIVO ET $i(IN VITRO) |
US20060178302A1 (en) | 1997-02-05 | 2006-08-10 | Northwestern University & The University Of Southern California | Amyloid beta protein (globular assembly and uses thereof) |
US20030068316A1 (en) | 1997-02-05 | 2003-04-10 | Klein William L. | Anti-ADDL antibodies and uses thereof |
US6218506B1 (en) | 1997-02-05 | 2001-04-17 | Northwestern University | Amyloid β protein (globular assembly and uses thereof) |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
ES2253839T3 (es) | 1997-12-03 | 2006-06-01 | Neuralab, Ltd. | Supresion de cambios relacionados con amiloide beta en la enfermedad de alzheimer. |
WO2000039310A1 (fr) | 1998-12-29 | 2000-07-06 | The University Of Georgia Research Foundation, Inc. | Proteines hybrides de rubredoxine, systeme et methodes d'expression de proteine |
WO2000071671A2 (fr) | 1999-05-26 | 2000-11-30 | New York University | Nouveaux genes mutants dans la demence familiale britannique et la demence familiale danoise |
UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
PE20010212A1 (es) | 1999-06-01 | 2001-02-22 | Neuralab Ltd | Composiciones del peptido a-beta y procesos para producir las mismas |
JP2003531570A (ja) | 1999-07-27 | 2003-10-28 | アブジェニックス インク. | 神経障害に関連したポリペプチド蓄積を阻害する方法および組成物 |
JP4796725B2 (ja) | 1999-08-04 | 2011-10-19 | ユニバーシティ オブ サザン カリフォルニア | アミロイドβタンパク質(球状アセンブリー及びその使用) |
CA2388559A1 (fr) | 1999-11-29 | 2001-06-07 | Neurochem Inc. | Vaccin destine a la prevention et au traitement de la maladie d'alzheimer et d'autres maladies associees aux substances amyloides |
WO2001090182A2 (fr) | 2000-05-22 | 2001-11-29 | New York University | Peptides immunogenes synthetiques mais non-amyloidogenes homologues de beta-amyloide, destines a induire une reaction immunitaire contre les peptides beta-amyloide et les depots amyloides |
EP1309341A2 (fr) | 2000-07-07 | 2003-05-14 | Lars Lannfelt | Prevention et traitement de la maladie d'alzheimer |
US20030187011A1 (en) | 2001-12-20 | 2003-10-02 | Lashuel Hilal A. | Apomorphine inhibitors of amyloid-beta (Abeta) fibril formation and their use in amyloidosis based disease |
WO2003089460A1 (fr) | 2002-04-19 | 2003-10-30 | The Governing Council Of The University Of Toronto | Methodes et compositions immunologiques pour le traitement de la maladie d'alzheimer |
US20040049134A1 (en) | 2002-07-02 | 2004-03-11 | Tosaya Carol A. | System and methods for treatment of alzheimer's and other deposition-related disorders of the brain |
WO2004024090A2 (fr) | 2002-09-12 | 2004-03-25 | The Regents Of The University Of California | Immunogenes et anticorps correspondant specifiques pour des intermediaires d'agregation de poids moleculaire eleve communs a des amyloides constitues par des proteines de sequences differentes |
JP2006508072A (ja) | 2002-10-01 | 2006-03-09 | ノースウエスタン ユニバーシティ | アミロイドベータ由来拡散性リガンド(ADDLs)、ADDL代替物、ADDL結合性分子、およびそれらの使用 |
US20070099185A1 (en) | 2002-11-04 | 2007-05-03 | Bioarctic Neuroscience Ab | Methods for the identification of agents that modulate the structure and processing of beta-amyloid precursor protein |
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
US20050124016A1 (en) | 2003-08-01 | 2005-06-09 | Enh Research Institute | Antibodies specific for toxic amyloid beta protein oligomers |
WO2005019828A1 (fr) | 2003-08-20 | 2005-03-03 | Amorfix Life Sciences Ltd. | Dosage de protection d'epitope et procede de detection de conformations proteiques |
EP1660533A4 (fr) | 2003-09-12 | 2009-10-21 | Univ California | Anticorps monoclonaux specifiques a des intermediaires d'agregation de poids moleculaire eleve communs a des amyloides formes a partir de proteines de sequence differente |
SE0400707D0 (sv) | 2004-03-22 | 2004-03-22 | Bioarctic Neuroscience Ab | Transgenic animal model |
SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
US8507206B2 (en) | 2004-07-02 | 2013-08-13 | Northwestern University | Monoclonal antibodies that target pathological assemblies of amyloid β (Abeta) |
US20060079447A1 (en) * | 2004-10-08 | 2006-04-13 | Wetzel Ronald B | Stabilized A-beta protofibrillar aggregates |
WO2006047254A1 (fr) | 2004-10-22 | 2006-05-04 | Regents Of The University Of Minnesota | Ensembles de proteines beta-amyloides oligomeres et utilisations de ceux-ci |
US7780963B2 (en) * | 2004-10-25 | 2010-08-24 | Merck & Co., Inc. | Anti-ADDL antibodies and uses thereof |
US20060240486A1 (en) * | 2004-12-15 | 2006-10-26 | Johnson-Wood Kelly L | Immunoprecipitation-based assay for predicting in vivo efficacy of beta-amyloid antibodies |
EP1853299A4 (fr) | 2005-01-14 | 2009-11-11 | Univ California | Compositions et methodes d'inhibition de la formation de drusen et methodes de diagnostic ou de traitement de pathologies liees aux drusen |
GT200600031A (es) | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
US7700099B2 (en) | 2005-02-14 | 2010-04-20 | Merck & Co., Inc. | Non-immunostimulatory antibody and compositions containing the same |
US7731962B2 (en) | 2005-02-14 | 2010-06-08 | Merck & Co., Inc. | Anti-ADDL monoclonal antibody and use thereof |
ES2340414T3 (es) | 2005-03-05 | 2010-06-02 | ABBOTT GMBH & CO. KG | Metodo de seleccion, proceso para la purificacion de oligomeros de a-beta no-difusibles, anticuerpos selectivos contra dichos oligomeros de a-beta no-difusibles y un proceso para la fabricacion de dichos anticuerpos. |
WO2006137354A1 (fr) | 2005-06-21 | 2006-12-28 | Medical & Biological Laboratories Co., Ltd. | Anticorps avec effet inhibiteur sur la formation de fibrilles amyloïdes |
TW200726774A (en) | 2005-06-30 | 2007-07-16 | Merck & Co Inc | Composition and method for producing stable amyloid beta oligomers |
TW200726482A (en) | 2005-06-30 | 2007-07-16 | Merck & Co Inc | Method for preparing a covalently cross linked oligomer of amyloid beta peptides |
CA2626783A1 (fr) | 2005-10-21 | 2007-05-03 | Merck & Co., Inc. | Anticorps monoclonal anti-addl et leur utilisation |
AU2006318537A1 (en) | 2005-11-22 | 2007-05-31 | The Trustees Of The University Of Pennsylvania | Antibody treatment of Alzheimer's and related diseases |
EP2325209A3 (fr) * | 2006-03-23 | 2011-08-03 | BioArtic Neuroscience AB | Anticorps améliorés sélectifs de protofibrilles et leur utilisation |
TW201815827A (zh) * | 2006-07-14 | 2018-05-01 | 瑞士商Ac免疫公司 | 抗β-類澱粉抗體或其抗原結合片段、其用途及使用方法 |
UA100672C2 (en) * | 2006-07-14 | 2013-01-25 | Ас Иммуне Са | HUMANIZED ANTIBODY TO b-AMYLOID PROTEIN |
BRPI0719763A2 (pt) * | 2006-10-02 | 2014-01-28 | Ac Immune Sa | Anticorpo, molécula de ácido nucleico, vetor de expressão, célula, composição, mistura, uso de um anticorpo quimérico ou um fragmento do mesmo ou um anticorpo humanizado ou um fragmento do mesmo e/ou uma parte funcional e/ou uma composição farmacêutica ou uma mistura, métodos para a preparação de uma composição farmacêutica ou de uma mistura, para prevenir, tratar ou aliviar os efeitos de uma doença, de diagnóstico de uma doença ou condição associada com amilóide em um paciente e de determinação do grau da carga de placa amiloidogênica em um tecido e/ou fluidos corporais, kits de teste para a detecção e diagnóstico de doenças e condições associadas com amilóide, região variável de cadeia leve, região variável de cadeia pesada, linhagem de célula, gene de anticorpo, e, métodos para desagregar fibras de beta-amilóide pré formadas, para prevenir a degradação de neurônio induzida por abeta, para diagnosticar uma predisposição a uma doença ou condição associada com amilóide em um paciente, para monitorar doença residual mínima em um paciente, para prognosticar a responsividade de um paciente que é tratado com um anticorpo ou uma composição de vacina, para reduzir a carga de placa no cérebro de um animal, para reduzir a quantidade de placas no cérebro de um animal, para diminuir a quantidade total de abeta solúvel no cérebro de um animal e para reter ou aumentar a capacidade de memória cognitiva em um mamífero. |
JP5749009B2 (ja) * | 2007-08-13 | 2015-07-15 | バスジーン セラピューティクス,インコーポレイテッドVasgenetherapeutics,Inc. | EphB4に結合するヒト化抗体を利用する癌治療剤 |
SI2202245T1 (sl) | 2007-09-26 | 2016-10-28 | Chugai Seiyaku Kabushiki Kaisha | Postopek modificiranja izoelektrične točke protitelesa preko aminokislinske substitucije v CDR |
EP2207568B1 (fr) * | 2007-11-16 | 2017-05-31 | The Rockefeller University | Anticorps spécifiques de la forme de protofibrille de protéine bêta-amyloïde |
ES2709048T3 (es) | 2008-04-29 | 2019-04-15 | Bioarctic Ab | Anticuerpos y vacunas para su uso en métodos terapéuticos y diagnósticos para trastornos relacionados con alfasinucleína |
BRPI1006448B1 (pt) | 2009-03-25 | 2021-08-17 | Genentech, Inc | Anticorpo antagonista anti-fgfr3, anticorpo monoclonal, polinucleotídeo, vetor, microorganismo transgênico, método para produção de um anticorpo anti-fgfr3, formulação farmacêutica e usos do anticorpo antagonista anti-fgfr3 |
HUE053949T2 (hu) | 2009-06-29 | 2021-08-30 | Bioarctic Ab | N-terminálisan csonkolt amiloid-B protofibrillumokra/oligomerekre szelektív ellenanyagok |
JP5692073B2 (ja) * | 2009-08-07 | 2015-04-01 | 協和発酵キリン株式会社 | 抗アミロイドβオリゴマーヒト化抗体 |
WO2011104696A1 (fr) * | 2010-02-26 | 2011-09-01 | Bioarctic Neuroscience Ab | Anticorps se liant aux protofibrilles et utilisation associée dans des méthodes thérapeutiques et diagnostiques pour la maladie de parkinson, la démence à corps de lewy et d'autres alpha-synucléinopathies |
CA2806252C (fr) * | 2010-07-29 | 2019-05-14 | Xencor, Inc. | Anticorps dont les points isoelectriques sont modifies |
ES2720136T3 (es) | 2010-12-22 | 2019-07-18 | Teva Pharmaceuticals Australia Pty Ltd | Anticuerpo modificado con semivida mejorada |
-
2015
- 2015-07-08 CN CN201580036189.2A patent/CN106661103B/zh active Active
- 2015-07-08 WO PCT/EP2015/065633 patent/WO2016005466A2/fr active Application Filing
- 2015-07-08 MA MA40224A patent/MA40224B1/fr unknown
- 2015-07-08 TW TW104122215A patent/TWI678376B/zh active
- 2015-07-08 JP JP2017500897A patent/JP6628786B2/ja active Active
- 2015-07-08 DK DK15738876.0T patent/DK3166970T3/da active
- 2015-07-08 SG SG11201610734RA patent/SG11201610734RA/en unknown
- 2015-07-08 MA MA053887A patent/MA53887A/fr unknown
- 2015-07-08 SI SI201531593T patent/SI3166970T1/sl unknown
- 2015-07-08 PE PE2017000024A patent/PE20170768A1/es unknown
- 2015-07-08 CN CN202011054114.6A patent/CN112390881A/zh active Pending
- 2015-07-08 LT LTEP15738876.0T patent/LT3166970T/lt unknown
- 2015-07-08 HU HUE15738876A patent/HUE053809T2/hu unknown
- 2015-07-08 KR KR1020237024350A patent/KR20230129449A/ko not_active Application Discontinuation
- 2015-07-08 AU AU2015286707A patent/AU2015286707B2/en active Active
- 2015-07-08 EP EP21154511.6A patent/EP3865510A3/fr active Pending
- 2015-07-08 CA CA2951990A patent/CA2951990C/fr active Active
- 2015-07-08 RS RS20210459A patent/RS61717B1/sr unknown
- 2015-07-08 PL PL15738876T patent/PL3166970T3/pl unknown
- 2015-07-08 KR KR1020167037100A patent/KR102564384B1/ko active IP Right Grant
- 2015-07-08 IL IL282823A patent/IL282823B2/en unknown
- 2015-07-08 JO JOP/2015/0167A patent/JO3537B1/ar active
- 2015-07-08 MX MX2017000378A patent/MX2017000378A/es unknown
- 2015-07-08 AR ARP150102178A patent/AR101130A1/es unknown
- 2015-07-08 RU RU2017103446A patent/RU2700104C2/ru active
- 2015-07-08 EP EP15738876.0A patent/EP3166970B1/fr active Active
- 2015-07-08 MY MYPI2017700010A patent/MY184890A/en unknown
- 2015-07-08 US US14/794,172 patent/US9573994B2/en active Active
- 2015-07-08 ES ES15738876T patent/ES2865112T3/es active Active
- 2015-07-08 UA UAA201700962A patent/UA121550C2/uk unknown
- 2015-07-08 PT PT157388760T patent/PT3166970T/pt unknown
-
2017
- 2017-01-05 PH PH12017500032A patent/PH12017500032A1/en unknown
- 2017-01-09 CL CL2017000053A patent/CL2017000053A1/es unknown
- 2017-01-09 IL IL250001A patent/IL250001B/en active IP Right Grant
- 2017-01-13 CO CONC2017/0000346A patent/CO2017000346A2/es unknown
- 2017-09-15 ZA ZA2017/06272A patent/ZA201706272B/en unknown
-
2021
- 2021-04-29 HR HRP20210680TT patent/HRP20210680T1/hr unknown
- 2021-06-01 CY CY20211100477T patent/CY1124563T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA40224B1 (fr) | Anticorps se liant aux protofibrilles ass améliorés | |
MA41060A (fr) | Compositions comprenant des souches bactériennes | |
MA55434B1 (fr) | Compositions comprenant des souches bactériennes | |
MX338421B (es) | Anticuerpos fosfoespecificos que reconocen la proteina tau. | |
MA41010A (fr) | Compositions comprenant des souches bactériennes | |
MA40755B1 (fr) | Compositions comprenant des souches bactériennes | |
MA40754B1 (fr) | Compositions comprenant des souches bactériennes | |
MA47313B1 (fr) | Formulations sous-cutanées d'anticorps her2 | |
MX354662B (es) | Anticuerpos fosfoespecificos que reconocen la tau. | |
MX356800B (es) | Anticuerpo tau humanizado. | |
MY171300A (en) | Pharmaceutical composition | |
MA43113B1 (fr) | Anticorps anti-htr a1 et méthodes d'utilisation de ceux-ci | |
MA44426B1 (fr) | Compositions et méthodes pour diminier l'expression de tau | |
MA38349A1 (fr) | Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3) | |
MA45172B1 (fr) | Arn modifié codant pour des polypeptides vegf-a, formulations et utilisations associées | |
WO2015117088A3 (fr) | Réactifs à base d'anticorps qui reconnaissent spécifiquement les formes de la protéine tdp-43 associées à une maladie neurodégénérative | |
MA38369A1 (fr) | Peptides et compositions pour le traitement d'une lesion de l'articulation | |
EP4233901A3 (fr) | Compositions pharmaceutiques contenant des anticorps anti-bêta-amyloïdes | |
MX2021011596A (es) | Compuestos y composiciones como moduladores de se?alizacion tlr. | |
MA39319A1 (fr) | Inhibiteur de la protéine de transfert d'ester de cholestéryle (cetp) et compositions pharmaceutiques comprenant ledit inhibiteur pour leur utilisation dans le traitement ou la prévention de maladies cardiovasculaires | |
WO2014053110A3 (fr) | Peptide pour le traitement et le diagnostic précoce de la maladie d'alzheimer et d'autres tauopathies | |
MA44660B1 (fr) | (+) -azasetron pour son utilisation dans le traitement des troubles de l'oreille | |
EA202090961A1 (ru) | Антитела к -синуклеину и их применения | |
MA42017B1 (fr) | Anticorps anti-cd154 offrant des caractéristiques de liaison, fonctionnalité et sécurité améliorées et son utilisation dans l'immunothérapie humaine | |
EA201992245A1 (ru) | Аналитические и терапевтические способы и композиции и их применение |